BIOE Bio Essence Corp
Pharmaceutical Preparations · OTC · SEC CIK 1723059 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY435.2%
TTM net income YoY943.9%
TTM EPS YoY—
Revenue 3-yr CAGR46.9%
Net income 3-yr CAGR—
Margins
Gross margin68.4%
Operating margin45.1%
Net margin44.7%
FCF margin—
EBITDA margin54.3%
Returns
ROE—
ROA64.7%
ROIC (approx.)—
Asset turnover1.45x
Leverage & solvency
Liabilities / assets42.7%
Debt / equity0.02x
Current ratio0.17x
Interest coverage-286.41x
Cash quality & payout
Operating cash flow / net income0.38x
Accruals ratio39.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $253,020 | $794,711 | $500,537 | $1.48M | $136,800 | $259,123 | $22,189 | $147,555 |
| Cost of revenue | $113,859 | $324,450 | $181,184 | $336,033 | $41,040 | $90,479 | $1,601 | $40,657 |
| Gross profit | $139,161 | $470,261 | $319,353 | $1.14M | $95,760 | $168,644 | $20,588 | $106,898 |
| SG&A expense | $298,286 | $190,971 | $102,878 | $113,794 | $80,857 | $107,421 | $225,137 | $103,046 |
| Operating income | -$159,125 | $279,290 | $215,795 | $1.03M | $14,253 | $61,223 | -$205,092 | $3,852 |
| Interest expense | -$3,508 | -$2,342 | $542 | $540 | $556 | $547 | $543 | $536 |
| Pretax income | -$155,625 | $280,488 | $215,212 | $1.03M | $12,998 | $60,664 | -$205,752 | -$27,563 |
| Income tax | -$5,167 | $10,411 | $9,839 | $0 | $0 | $800 | — | $0 |
| Net income | -$150,458 | $270,077 | $205,373 | $1.03M | $12,998 | $59,864 | -$205,752 | -$27,563 |
| EBITDA | $15,875 | $382,890 | $215,854 | $1.03M | $14,311 | $61,282 | -$205,033 | $3,910 |
| EPS (basic) | — | — | — | — | — | 0.00 | -0.01 | — |
| EPS (diluted) | — | — | — | — | — | 0.00 | -0.01 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $201,511 | $675 | $36,177 | — | $28,741 | — | — | $1,371 |
| Receivables | — | — | $5,319 | $23,454 | $4,969 | $4,969 | $8,191 | $5,124 |
| Current assets | $278,919 | $606,507 | $788,994 | $422,377 | $184,378 | $112,477 | $365,444 | $280,692 |
| Intangibles | $3.22M | $3.40M | $38 | $97 | $3.22M | $3.40M | $274 | $332 |
| Total assets | $4.00M | $4.00M | $789,032 | $422,474 | $184,534 | $112,692 | $365,718 | $281,024 |
| Current liabilities | $1.65M | $1.61M | $2.16M | $2.44M | $3.23M | $3.07M | $3.24M | $2.80M |
| Long-term debt | $56,519 | $56,836 | $57,160 | $57,482 | $57,806 | $58,122 | $56,164 | $56,481 |
| Total debt | $56,519 | $56,836 | $57,160 | $57,482 | $57,806 | $58,122 | $56,164 | $56,481 |
| Total liabilities | $1.71M | $1.66M | $2.22M | $2.50M | $3.29M | $3.23M | $3.54M | $3.25M |
| Shareholders' equity | $2.29M | $2.34M | -$1.43M | -$2.07M | -$3.10M | -$3.11M | -$3.17M | -$2.97M |
| Net debt | -$144,992 | $56,161 | $20,983 | — | $29,065 | — | — | $55,110 |
| Shares outstanding | 55.81M | 53.81M | 46.81M | 38.01M | 38.01M | 38.01M | 38.01M | 38.01M |
| Cash flow statement | ||||||||
| Operating cash flow | -$368,848 | $59,650 | -$411,970 | $1.24M | $186,973 | $167,797 | -$26,069 | $423,066 |
| Investing cash flow | $470,000 | — | — | — | — | — | — | — |
| Financing cash flow | $99,684 | -$10,325 | $448,147 | -$1.27M | -$158,232 | -$167,797 | $24,698 | -$451,513 |
| Depreciation & amortization | $175,000 | $103,600 | $59 | $59 | $58 | $59 | $59 | $58 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.